Neprilysin

PHILADELPHIA — In a real-world population of patients hospitalized for HF with reduced ejection fraction, sacubitril/valsartan was associated with reduced risk for mortality and rehospitalization at 12 months, according to findings presented at the Heart Failure Society of America Scientific Meeting.

PHILADELPHIA — Right ventricular enlargement, left ventricular hypertrophy and elevated left- and right-sided pressures were among the predictors of HF hospitalization or CV death among patients with HF with preserved ejection fraction, according to data from the PARAGON-HF echocardiographic substudy.

The European Society of Cardiology Congress, which is being held Aug. 31 to Sept. 4 in Paris, will feature late-breaking clinical science presentations that have the potential to have a significant impact on CV care.